- ChromaDex Corp (NASDAQ: CDXC) enters into a securities purchase agreement to sell $25 million in common stock via a private placement led by a new international investor.
- The company will sell around 3.8 million shares at $6.50 per share, representing a discount of 22% on the last close price of $8.31 on Friday.
- The placement will close by February 23.
- ChromaDex plans to use the proceeds to accelerate the Tru Niagen brand's growth, advance clinical research on NAD+ precursors, and support general corporate purposes.
- Price Action: CDXC shares are down 3.49% at $8.02 in the pre-market session on the last check Monday.
Loading...
Loading...
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
